logo
  Join        Login             Stock Quote

About Those Ssris (And Other Drugs)

 January 29, 2013 04:13 PM


I shouldn't be surprised at any sort of scam in any industry, really.  With the destruction of the rule of law and the buying of our government the sort of behavior that we've seen by banksters is utterly common, such as what UBS did with screwball "bonds" that were in fact synthetic PUTs -- and a bad deal whether you knew what you were buying or not.

But when it comes to studies of various sorts, consider something simple -- the flip of a coin.  You and I agree that we will study how coins fall when flipped.  I tell you that I will run 100 studies on this.

You of course expect me to report something near 50 heads and 50 tails.  But when you get the results you are astonished to find that I reported 100 "heads."

[Related -Chart Says This Retailer's Comeback Isn't Finished]

You conclude that I am flipping a 2-headed coin, of course.

I'm not.

I'm only reporting the trials that come up heads, and ignoring those that come up "tails"!

Most people would call this fraud.

Drug companies appear to call this how we do business.

We'll do one more. In 2006, researchers looked into every trial of psychiatric drugs in four academic journals over a 10-year period, finding 542 trial outcomes in total. Industry sponsors got favorable outcomes for their own drug 78 percent of the time, while independently funded trials only gave a positive result in 48 percent of cases. If you were a competing drug put up against the sponsor's drug in a trial, you were in for a pretty rough ride: You would only win a measly 28 percent of the time.

[Related -ETF Performance Review: Major Asset Classes | 19 Dec 2014]

Now this sounds bad.  But it's actually far worse than it sounds, because the outcome for a drug trial is not simply "does it help people or not."  There is a third possibility: It might harm or even kill the person who takes it.

This is not an academic exercise -- it's real.  The only way to know if something works when it comes to medical research is to test it, but in many cases the test results are not published.  There is no legal requirement that all such trials be made public or that prior art -- and the results of such tests -- be disclosed.

So what happens?  You get screwed. 

The worst part of it is that this sort of harm is not limited to you, particularly when it comes to medications that bear not on a physical ailment but a psychiatric one.  When someone goes nuts their behavior can impact others, and sometimes in dramatic and horrifying ways.

Like, for instance, in Aurora.  Or, for that matter, perhaps at Sandy Hook.

Never mind the people who think they're taking a drug to treat or prevent some disease and wind up with either a drug that doesn't work, or worse, one that injures or kills them. That happens fairly frequently.

We call it practicing medicine for a reason; there is no guarantee of success.  You are the one being practiced upon, to put not-to-fine a point on it!

But we, the people, should tolerate nothing less than all the data.  Burying information that is unflattering to a particular compound or company, if harm later is detected that could have been avoided if that data had been published, should be defined as what it is: Criminal assault and fraud, with both personal and corporate liability for everyone involved.

We'll never get to the truth of what works and what doesn't -- and what the risks are associated with what works -- until and unless we make this change.

If President Obama, Herr Biden and the rest are seriously interested in advancing public health, especially mental health, this is one change that could be made and would pay real dividends -- and where the "costs" would all be in the form of putting a stop to ill-gotten gains that were in fact garnered by screwing people.

If you want to do something "for the children", this is it.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.